An article in the March 9, 2005, issue of BioWorld Today should have said Onyx Pharmaceuticals Inc.'s cash, cash equivalents and marketable securities totaled about $209.6 million as of Dec. 31.

Editor's Note: The correction has been made in BioWorld Online.